View Post

Breast-Conserving Surgery Safe for Deeply Seated Breast Cancer

In In The News by Barbara Jacoby

By: Deborah L. Ungerleider, MD From: medscape.com The study covered in this summary was published on ResearchSquare.com as a preprint and has not yet been peer reviewed. Key Takeaways When performing breast-conserving surgery, the retroglandular approach via incision in the inframammary fold for excision of a retroglandular tumor is feasible and safe. This incision gives better cosmetic results while allowing …

View Post

Hypofractionated RT: A Potential New Standard Treatment for Certain Breast Cancers

In Clinical Studies News by Barbara Jacoby

By: Leah Lawrence From: cancertherapyadvisor.com A new study suggested that moderately hypofractionated whole-breast irradiation was safe and effective, and could be recommended as a standard therapy for breast-only radiotherapy in women who undergo breast-conserving surgery for node-negative early breast cancer. The study randomly assigned 1854 women to receive radiotherapy at either 50 Gy in 25 fractions or the hypofractionated rate …

View Post

Breast cancer recurrence after lumpectomy & RT is treatable with localized RT without mastectomy

In In The News by Barbara Jacoby

Source: NRG Oncology From: eurekalert.org NRG Oncology trial shows that breast cancer recurrence after lumpectomy and radiation is treatable with localized radiation without mastectomy Approximately 10% of breast cancer patients treated with lumpectomy (breast-conserving surgery [BCS]) and whole-breast radiation (WBI) will have a subsequent in-breast local recurrence of cancer (IBTR) when followed long term. The surgical standard of care has …

View Post

Lumicell Completes Enrollment of Phase C Feasibility Trial for Breast Cancer Surgical Guidance Solution

In Clinical Studies News by Barbara Jacoby

From: biospace.com Lumicell, Inc., an innovation leader in image guided cancer surgery, today announced that it has completed enrollment in its Phase C feasibility clinical trial of the Lumicell Imaging System for breast cancer. With results from the Phase C feasibility trial expected in late 2019, Lumicell expects to begin the pivotal trial by the end of 2019 before applying …

View Post

Local Surgeon Reports Positive Findings from Use of 3D Marker in Breast Cancer Treatment

In In The News by Barbara Jacoby

Better Cosmetic Outcomes and Shorter Radiation Therapy Seen in Study Results A research study by local surgical oncologist Michael Cross, M.D., F.A.C.S., concluded that use of the BioZorb® surgical marker appears to provide better cosmetic outcomes and may be associated with an increased use of breast-conserving surgery in his practice. The study found that more than 90% of patients who …